Literature DB >> 27701912

Impact of metformin on the progression of MGUS to multiple myeloma.

Ben Boursi1,2, Ronac Mamtani1,2, Yu-Xiao Yang2,3, Brendan M Weiss1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27701912      PMCID： PMC5371023          DOI： 10.1080/10428194.2016.1236375

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  17 in total

1.  Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.

Authors:  Jason LeGrand; Eun Sung Park; Hongyang Wang; Shalu Gupta; James D Owens; Patrick J Nelson; Wendy DuBois; Thomas Bair; Siegfried Janz; J Frederic Mushinski
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

Review 2.  Investigating metformin for cancer prevention and treatment: the end of the beginning.

Authors:  Michael N Pollak
Journal:  Cancer Discov       Date:  2012-08-27       Impact factor: 39.397

3.  Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States.

Authors:  L M Brown; G Gridley; L M Pottern; D Baris; C A Swanso; D T Silverman; R B Hayes; R S Greenberg; G M Swanson; J B Schoenberg; A G Schwartz; J F Fraumeni
Journal:  Cancer Causes Control       Date:  2001-02       Impact factor: 2.506

4.  Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.

Authors:  M Ferlin; N Noraz; C Hertogh; J Brochier; N Taylor; B Klein
Journal:  Br J Haematol       Date:  2000-11       Impact factor: 6.998

Review 5.  Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

Authors:  Andrea Decensi; Matteo Puntoni; Pamela Goodwin; Massimiliano Cazzaniga; Alessandra Gennari; Bernardo Bonanni; Sara Gandini
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-12

6.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  A monoclonal gammopathy precedes multiple myeloma in most patients.

Authors:  Brendan M Weiss; Jude Abadie; Pramvir Verma; Robin S Howard; W Michael Kuehl
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

8.  Cancer incidence in The Health Improvement Network.

Authors:  Kevin Haynes; Kimberly A Forde; Rita Schinnar; Patricia Wong; Brian L Strom; James D Lewis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-08       Impact factor: 2.890

9.  Validity and completeness of colorectal cancer diagnoses in a primary care database in the United Kingdom.

Authors:  Lucía Cea Soriano; Montse Soriano-Gabarró; Luis A García Rodríguez
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-10-05       Impact factor: 2.890

Review 10.  Metformin and the risk of cancer: time-related biases in observational studies.

Authors:  Samy Suissa; Laurent Azoulay
Journal:  Diabetes Care       Date:  2012-12       Impact factor: 19.112
View more
  7 in total

Review 1.  Metformin and Cancer, an Ambiguanidous Relationship.

Authors:  Sarah J Skuli; Safwan Alomari; Hallie Gaitsch; A'ishah Bakayoko; Nicolas Skuli; Betty M Tyler
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-19

2.  Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.

Authors:  Su-Hsin Chang; Jason Gumbel; Suhong Luo; Theodore S Thomas; Kristen M Sanfilippo; Jingqin Luo; Graham A Colditz; Kenneth R Carson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-09-09       Impact factor: 4.254

3.  Elucidating Under-Studied Aspects of the Link Between Obesity and Multiple Myeloma: Weight Pattern, Body Shape Trajectory, and Body Fat Distribution.

Authors:  Catherine R Marinac; Catherine A Suppan; Edward Giovannucci; Mingyang Song; Ane S Kværner; Mary K Townsend; Bernard A Rosner; Timothy R Rebbeck; Graham A Colditz; Brenda M Birmann
Journal:  JNCI Cancer Spectr       Date:  2019-06-24

4.  Influence of metformin on HIF-1 pathway in multiple myeloma.

Authors:  Kinga A Kocemba-Pilarczyk; Sonia Trojan; Barbara Ostrowska; Małgorzata Lasota; Paulina Dudzik; Dorota Kusior; Marta Kot
Journal:  Pharmacol Rep       Date:  2020-07-27       Impact factor: 3.024

5.  The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo.

Authors:  Beatriz Gámez; Emma V Morris; Sam W Z Olechnowicz; Siobhan Webb; James R Edwards; Aneka Sowman; Christina J Turner; Claire M Edwards
Journal:  Transl Oncol       Date:  2021-12-08       Impact factor: 4.243

Review 6.  Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.

Authors:  Michael H Tomasson; Mahmoud Ali; Vanessa De Oliveira; Qian Xiao; Yogesh Jethava; Fenghuang Zhan; Adam M Fitzsimmons; Melissa L Bates
Journal:  Int J Mol Sci       Date:  2018-11-16       Impact factor: 5.923

7.  Type 2 diabetes mellitus does not increase the risk of multiple myeloma: a systematic review and meta-analysis.

Authors:  Chenlu Zhang; Yuou Sha; Haiyan Liu; Dan Guo; Yijing Jiang; Lemin Hong; Lili Shi; Hongming Huang
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.